NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
79.16 +0.16 (+0.20%) GOLD FUTURES
2,315.50 +4.50 (+0.19%) DOW
38,244.04 +340.75 (+0.90%) Bitcoin GBP
47,190.60 +536.45 (+1.15%)
AstraZeneca PLC (AZNCF)
| Previous close | 151.02 |
| Open | 153.88 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 153.48 - 153.88 |
| 52-week range | 118.16 - 153.88 |
| Volume | |
| Avg. volume | 4,406 |
| Market cap | 238.649B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 37.90 |
| EPS (TTM) | 4.05 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 2.86 (1.89%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
Fool.co.uk£20,000 in cash? Here’s how I’d aim for £10,000 in annual passive income!
Our writer explains how he'd maximise his investment allowance in a Stocks and Shares ISA to target £10k in tax-free passive income every year. The post £20,000 in cash? Here’s how I’d aim for £10,000 in annual passive income! appeared first on The Motley Fool UK.
